[KSCI] Korea Science Citation Index Service

http://dx.doi.org/10.9708/jksci.2020.25.11.179

Impact Factors and Validity of Blood Variables on Death in COVID-19 patient: Using Data of Korea Disease Control and Prevention Agency

Kim, Yu-Rin (Dept. of Dental Hygiene, Sila University)
Nam, Seoul-Hee (Dept. of Dental Hygiene, Kangwon National University)
Kim, Seon-Rye (Dept. of Pharmacy, Kangwon National University)

Publication Information

Journal of the Korea Society of Computer and Information / v.25, no.11, 2020 , pp. 179-185 More about this Journal

Abstract

In this paper, we propose impact factors and validity of blood variables on death of COVID-19 patients. The clinical-epidemiological data of 5628 COVID-19 patients, provided from Korea Disease Control and Prevention Agency as day of 30th April 2020, were used. As results, impact factors of death were dementia, older age, high lymphocyte, cancer, dyspnea, COPD, change of consciousness, heart disease, high platelets, abnormal diastolic pressure and fever. The validities of blood variables for death were high in the order of lymphocyte, hemoglobin, hematocrit, platelet and WBC. Therefore, risk factors such as initial clinical characteristics, underlying disease and blood test results, could be regarded for efficient management of COVID-19 patients.

Keywords

COVID-19; Death; Impact factors; Blood variables; Validity;

Citations & Related Records

Reference

1	C. Viboud, R. F. Grais, B. A. Lafont, M. A. Miller and L. Simonsen. "Multinational Influenza Sasonal Mortality Study Group. Multinational impact of the 1968 Hong Kong influenza pandemic: evidence for a smoldering pandemic", Journal of Infectious Disease, Vol. 192, No. 2, pp.233-48. Jun 2005. DOI: 10.1086/431150 DOI
2	L. Simonsen, M. J. Clarke, L. B. Schonberger, N. H. Arden and N. J. Cox. "Pandemic versus epidemic influenza mortality: a pattern of changing age distribution", Journal of Infectious Disease, Vol. 178, No. 1, pp. 53-60. Jul. 1998 DOI: 10.1086/515616. DOI
3	S. Rewar, D. Mirdha and P. Rewar. "Treatment and prevention of pandemic H1N1 Influenza". Annual Global Health, Vol. 81, No. 5, pp. 645-53. September 2015 DOI: 10.1016/j.aogh.2015.08.014 DOI
4	Korean Ministry of Health and Welfare. 2020. http://ncov.mohw.go.kr/
5	Coronaboard. 2020. https://coronaboard.kr/
6	World Coronaboard. 2020. retrieved from https://covid19.apthowmuch.com/
7	A. E. Gorbalenya, S. C. Baker and R. S. Baric. "The species Severe acute respiratory syndromerelated coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2" Nature Microbiology, Vol. 5, No. 4, pp. 536-544. March 2020 Doi: 10.1038/s41564-020-0695-z. DOI
8	A. Giacomelli, L. Pezzati and F. Conti. "Self-reported olfactory and taste disorders in SARSCoV-2 patients: a cross-sectional study", Clinical Infectious Diseases, Vol. 71, No. 15, pp.ciaa330, March 2020 Doi: 10.1093/cid/ciaa330 DOI
9	S. H. Lee and J. M. Kim. "Coronavirus Disease 2019 (COVID-19) Pandemic and the Challenge of Public Health." Korean Journal of Family Practice. Vol. 10, No. 2, pp.87-95. April 2020 DOI: 10.21215/kjfp.2020.10.2.87 DOI
10	A. Saglietto, F. D'Ascenzo, G. B. Zoccai and G. M. FerrarH. "COVID-19 in Europe: the Italian lesson". Lancet, Vol. 395, No. 10230, pp. 1110-1111. Arpil 2020 DOI: 10.1016/S0140-6736(20)30690-5. DOI
11	W. Ji, K. Huh, M. Kang, J. Hong, G. H. Bae, R. Lee, Y. Na, H. Choi, S. Y. Gong, Y. H. Choi, K. P. Ko, J. S. Im and J. Jung. "Effect of Underlying Comorbidities on the Infection and Severity of COVID-19 in Korea: A Nationwide Case-Control Study". Journal of Korean Medication Science. Vol. 35, No. 25, pp.e237. Jun 2020 DOI: 10.3346/jkms.2020.35.e237 DOI
12	N. Chen, M. Zhou, X. Dong, J. Qu. F. Gong, Y. Han and L. Zhang. "Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study". Lancet Vol. 395, No. 10223, pp.507-13. Feb. 2020 DOI: 10.1016/S0140-6736(20)30211-7 DOI
13	W. J. Guan, Z.Y. Ni, Y. Hu, W. H. Liang, C. Q. Ou and J. X. He. "Clinical characteristics of coronavirus disease 2019 in China" New England journal of medicine, Vol. 58, No. 3, pp.711-712. April 2020 Doi: 10.1056/NEJMoa2002032. DOI
14	D. Wang, B. Hu, C. Hu, F. Zhu, X. Liu and J. Zhang. "Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China". JAMA, Vol. 323, No. 11, pp.1061-1069. Feb. 2020 Doi: 10.1001/jama.2020.1585. DOI
15	Chinese Center for Disease Control and Prevention. Epidemic update and risk assessment of 2019 novel coronavirus [Internet]. Beijing: Chinese Center for Disease Control and Prevention; 2020 [cited 2020 Apr 14]. Available: http://www.chinacdc.cn/yyrdgz/202001/P020200128523354919292.pdf.
16	G. M. Kuster, O. Pfister, T. Burkard, Q. Zhou, R. Twerenbold and P. Haaf. "SARSCoV2: should inhibitors of the renin-angiotensin system be withdrawn in patients with COVID-19?" European Heart Journal, Vol. 41, No. 19, pp. ehaa235. March 2020 Doi: 10.1093/eurheartj/ehaa235. DOI
17	S. R. Weiss, S. Navas-Martin. Coronavirus pathogenesis and the emerging pathogen severe acute respiratory syndrome coronavirus. Microbiol Mol Biol Rev. Vol. 69, No. 4. December 2005 pp. 635 - 664. https://doi.org/10.1128/MMBR.69.4.635-664.2005. DOI
18	N. R. Sexton, E. Smith, H. Blanc, M. Vignuzzi, O. Peersen, M. R. Denison. Homology-based identification of a mutation in the coronavirus RNA dependent RNA polymerase that confers resistance to multiple mutagens. J Virol. Vol. 90, No. 16, pp. 7415-7428. Auguest 2016 https://doi.org/10.1128/JVI.00080-16 DOI